Legend Biotech Corporation (LEGN)

Legend Biotech Corporation's Q·Score is 6/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Consensus analyst target of $57.59 is 69% above current price. Key area to monitor: currently unprofitable (-22% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for LEGN is $57.59, based on ratings from 15 Wall Street analysts. This is 69.5% above the current price of $33.98. Price targets are forward-looking estimates and not guarantees of future performance.

Legend Biotech Corporation (LEGN) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 25.5×. The consensus analyst price target of $57.59 is 69% above the current price.

Legend Biotech Corporation's next earnings report is expected on approximately August 10, 2026.

Legend Biotech Corporation has a net profit margin of -22.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 55.0%, indicating a high-margin business model.

Legend Biotech Corporation is reporting strong year-over-year growth of 56.5%.

Legend Biotech Corporation has a debt-to-equity ratio of 0.40×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 2.13×, indicating comfortable short-term liquidity.